Targeted therapy with trastuzumab (Traz), a humanized IgG monoclonal antibody against the HER2 extracellular domain (ECD), has become a mainstay for patients with HER2-positive breast cancer (BC) and gastric cancer (GC) 3, 4. This evidence concerns the gene ERBB2 and breast carcinoma.